CaRISMA Study

verified Patient-friendly certified
The Sickle Cell 101 research team in collaboration with study investigator have reviewed this information to ensure it is patient-friendly and accurate.

About the study

To identify treatments that do not rely only on opioids or other medications. Participants will use their smartphone to answer questionnaires and interact with a mobile application.

Study point of contact

Charles Jonassaint, PhD, MHS
412-586-9850
[email protected]itt.edu

Locations

1 United States site

Genotypes

All SCD

Study type

Digital

Gender

All

Interventions

c-CBT, m-Education

Compensation

Yes

participation requirements

  • People with any type of sickle cell disease
  • Male or female, age 18 years or older
  • Reports chronic pain: i.e pain more days than not for the past 3 months or longer and/or is prescribed daily or long-acting opioids for pain.
  • English speaking

participation restrictions

  • Any potential participants who fail consent comprehension questions

Locations

  • United States [Recruiting]

More info

VIEW ON CLINICALTRIALS.GOV
Enroll Now
Last updated August 27, 2021